Silverstein Sells Shares of Abeona Therapeutics

Christine Berni Silverstein recently sold 18,160 shares of Abeona Therapeutics Inc. (NasdaqCM: ABEO) on June 15, 2026. The shares were sold at an average price of $5.71, bringing the total transaction value to approximately $103,693.60. This sale was not part of a pre-planned trading program.

Insider Buying and Selling at Abeona Therapeutics Inc.

Several insiders at Abeona Therapeutics made transactions in June. On June 9, Chief Commercial Officer Madhav Vasanthavada sold 5,450 shares at $5.30 each, while Brendan O'Malley, the SVP and Chief Legal Officer, sold 6,305 shares at the same price. Joseph Walter Vazzano, the Chief Financial Officer, executed planned sales of 25,646 and 39,067 shares at prices of $5.39 and $5.36, respectively. CEO Vishwas Seshadri also sold 31,916 shares at $5.30.

Other Institutional Activity in Abeona Therapeutics

Nantahala Capital Management added 50,000 shares to its holdings in Abeona Therapeutics, resulting in a total of 5,013,052 shares valued at roughly $22.46 million. BlackRock, Inc. also increased its position by 35,667 shares, finishing with 3,195,530 shares worth about $14.32 million. AIGH Capital Management made a significant move by adding 1,100,000 shares, bringing its total to 3,100,000 shares valued at $13.89 million. Cable Car Capital, LP increased its stake by 507,329 shares, ending with 3,007,329 shares valued at approximately $13.47 million.

Abeona Therapeutics Stock Snapshot

Shares of Abeona Therapeutics are currently trading around $5.53. The company has a market capitalization of about $315 million and a P/E ratio of 5.82. Abeona's stock has experienced a 52-week low of $4.00 and a high of $7.54. The 50-day moving average is $5.46, while the 200-day moving average is $5.26. The company maintains a solid financial position with a current ratio of 5.89 and a quick ratio of 5.64.

Recent Earnings

Abeona Therapeutics reported revenue of $14.54 million, reflecting its ongoing operations in gene and cell therapy development. The company achieved a net margin of 4.55% and a return on equity of 0.71%. Its next earnings announcement is expected on August 13, 2026.

Analysts Set New Price Targets

On March 10, 2026, HC Wainwright & Co. reiterated its 'buy' rating for Abeona Therapeutics with a price target of $20. The consensus among seven analysts is a 'buy' recommendation with a mean target price of $19.71.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a biopharmaceutical company based in Cleveland, Ohio, focusing on developing gene and cell therapies for severe diseases. Their pipeline includes ZEVASKYN for recessive dystrophic epidermolysis bullosa and several other treatments for genetic eye disorders. The company was founded in 1974 and is led by CEO Joseph Walter Vazzano.

Bottom Line

Insider transactions at Abeona Therapeutics, including the recent sale by Christine Berni Silverstein, are closely watched by investors. The company's stock remains an active area of interest, with institutional investors adjusting their positions. Abeona's financial health and innovative therapies continue to draw analyst attention, as reflected in the reiterated 'buy' ratings. As always, these filings are backward-looking and may not represent the current positions or future intentions of insiders or institutions.